Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -38.26 Million USD | -219.86% |
| 2021 | -115.43 Million USD | 85.03% |
| 2020 | -88.26 Million USD | 1.62% |
| 2019 | -88.01 Million USD | -62.17% |
| 2018 | -57.28 Million USD | -92.96% |
| 2017 | -29.68 Million USD | 22.56% |
| 2016 | -37.7 Million USD | -16.8% |
| 2015 | -32.24 Million USD | -51.09% |
| 2014 | -21.35 Million USD | -79.56% |
| 2013 | -12.09 Million USD | -56.98% |
| 2012 | -4.81 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 Q2 | -13.54 Million USD | 1.59% |
| 2022 Q3 | -9.01 Million USD | 33.46% |
| 2022 Q4 | -7.45 Million USD | 17.32% |
| 2022 Q1 | -13.76 Million USD | 24.94% |
| 2022 FY | - USD | -219.86% |
| 2021 Q1 | -20.69 Million USD | 8.69% |
| 2021 Q4 | -18.33 Million USD | -65.45% |
| 2021 Q2 | -14.23 Million USD | 31.22% |
| 2021 Q3 | -11.08 Million USD | 22.15% |
| 2021 FY | - USD | 85.03% |
| 2020 FY | - USD | 1.62% |
| 2020 Q4 | -22.66 Million USD | 0.67% |
| 2020 Q2 | -20.66 Million USD | 17.59% |
| 2020 Q3 | -22.81 Million USD | -10.43% |
| 2020 Q1 | -25.07 Million USD | -11.66% |
| 2019 Q4 | -22.45 Million USD | -6.86% |
| 2019 Q2 | -24.78 Million USD | -2.1% |
| 2019 FY | - USD | -62.17% |
| 2019 Q1 | -24.27 Million USD | -20.05% |
| 2019 Q3 | -21.01 Million USD | 15.23% |
| 2018 Q4 | -20.22 Million USD | -4.36% |
| 2018 Q2 | -3.61 Million USD | 73.6% |
| 2018 Q1 | -13.68 Million USD | -18.59% |
| 2018 FY | - USD | -92.96% |
| 2018 Q3 | -19.38 Million USD | -436.25% |
| 2017 Q4 | -11.54 Million USD | -75.86% |
| 2017 Q2 | -5.65 Million USD | 0.44% |
| 2017 Q1 | -5.67 Million USD | 40.9% |
| 2017 FY | - USD | 22.56% |
| 2017 Q3 | -6.56 Million USD | -16.14% |
| 2016 Q1 | -9.57 Million USD | -17.77% |
| 2016 FY | - USD | -16.8% |
| 2016 Q4 | -9.6 Million USD | -12.17% |
| 2016 Q3 | -8.56 Million USD | 17.47% |
| 2016 Q2 | -10.37 Million USD | -8.38% |
| 2015 FY | - USD | -51.09% |
| 2015 Q4 | -8.12 Million USD | 8.24% |
| 2015 Q3 | -8.85 Million USD | -14.22% |
| 2015 Q2 | -7.75 Million USD | 1.42% |
| 2015 Q1 | -7.86 Million USD | -15.05% |
| 2014 Q2 | -5.41 Million USD | -32.7% |
| 2014 FY | - USD | -79.56% |
| 2014 Q4 | -6.83 Million USD | -33.06% |
| 2014 Q3 | -5.13 Million USD | 5.01% |
| 2014 Q1 | -4.07 Million USD | -1.49% |
| 2013 Q4 | -4.01 Million USD | -23.75% |
| 2013 Q3 | -3.24 Million USD | 0.0% |
| 2013 FY | - USD | -56.98% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | -8454.814% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -29.685% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 66.45% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -142.783% |
| Better Therapeutics, Inc. | -38.26 Million USD | -0.008% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -113.931% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -13.435% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -14.659% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 64.018% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | -4088.958% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -17.804% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 18.048% |
| Innovation1 Biotech Inc. | -5.68 Million USD | -573.235% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -134.737% |
| Molecular Templates, Inc. | 1.43 Million USD | 2775.874% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -175.782% |
| NexImmune, Inc. | -28.16 Million USD | -35.848% |
| Orgenesis Inc. | -60.71 Million USD | 36.979% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 25.401% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | -52020.791% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -137.004% |
| Scopus BioPharma Inc. | -11.71 Million USD | -226.684% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 92.913% |
| Statera Biopharma, Inc. | 38.93 Million USD | 198.279% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -455.854% |
| Trevena, Inc. | -35.28 Million USD | -8.436% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -68168.184% |
| Vaccinex, Inc. | -19.74 Million USD | -93.766% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3554.805% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 18.345% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -426.848% |